ArticleScientific reports2022
Genome-wide aberrant methylation in primary metastatic UM and their matched metastases.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- Functional validation of driver mutation-specific uveal melanoma biomarkers: role of COL9A3 in cancer cell plasticity.The Journal of pathology · 2026Article
- Establishment of Uveal Melanoma Patient-Derived Organoids Using an Air-Liquid Interface System for Translational Research.Investigative ophthalmology & visual science · 2026Article
- Matched sampling reveals uncoupled phenotypic plasticity during metastasis formation in uveal melanoma.iScience · 2026Article
- Precision Oncology in Ocular Melanoma: Integrating Molecular and Liquid Biopsy Biomarkers.Current issues in molecular biology · 2026Review
- Methylated CfDNA may distinguish between high- and intermediate-risk uveal melanoma: a pilot study.Cancer cell international · 2025Article
- Genome-wide methylation profiles of primary and matched distant metastasis: insights from the Dutch Early-Stage melanoma (D-ESMEL) study.Human genomics · 2025Article
- Ubiquitin-conjugating enzyme E2S serves as a prognostic marker for skin cutaneous melanoma.Translational cancer research · 2025Article
- Clinical Value of MLPA for Prognostic Assessment of Chromosomal Rearrangements and DNA Methylation in Uveal Melanoma.Investigative ophthalmology & visual science · 2025Article
- Elevated Expression of STAT6, ERG, and miR-647 Expression as Predictive Biomarkers for Prostate Cancer.International journal of general medicine · 2025Article
- New perspectives on DNA methylation modifications in ocular diseases.International journal of ophthalmology · 2025Review
- Exploring recent advances in signaling pathways and hallmarks of uveal melanoma: a comprehensive review.Exploration of targeted anti-tumor therapy · 2025Review
- Genetic Features of Uveal Melanoma.Genes · 2024Review
- Article
- Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.Molecular biomedicine · 2024Review
- Pathological and Molecular Diagnosis of Uveal Melanoma.Diagnostics (Basel, Switzerland) · 2024Review
- Machine Learning Methods for Gene Selection in Uveal Melanoma.International journal of molecular sciences · 2024Article
- Biological characteristics and clinical management of uveal and conjunctival melanoma.Oncology research · 2024Review
- Genetic and Epigenetic Features of Uveal Melanoma-An Overview and Clinical Implications.International journal of molecular sciences · 2023Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Uveal melanoma (UM) is an aggressive intra-ocular cancer with a strong tendency to metastasize. Metastatic UM is associated with mutations in BAP1 and SF3B1, however only little is known about the epigenetic modifications that arise in metastatic UM. In this study we aim to unravel epigenetic changes contributing to UM metastasis using a new genome-wide methylation analysis technique that covers over 50% of all CpG's. We identified aberrant methylation contributing to BAP1 and SF3B1-mediated UM metastasis. The methylation data was integrated with expression data and surveyed in matched UM metastases from the liver, skin and bone. UM metastases showed no commonly shared novel epigenetic modifications, implying that epigenetic changes contributing to metastatic spreading and colonization in distant tissues occur early in the development of UM and epigenetic changes that occur after metastasis are mainly patient-specific. Our findings reveal a plethora of epigenetic modifications in metastatic UM and its metastases, which could subsequently result in aberrant repression or activation of many tumor-related genes. This observation points towards additional layers of complexity at the level of gene expression regulation, which may explain the low mutational burden of UM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.